Article
Tom Caravela
Career Resiliency: How to Survive and Thrive After a Lay Off
Summary
In this episode, Tom Caravela is joined by Carol Lawlor to discuss her career journey and the challenges faced in the medical affairs industry. Carol shares her personal experiences transitioning into the field, addressing the emotional impact of industry layoffs and offering strategies for job searching with resilience. She provides insightful advice on career progression and highlights emerging roles in medical affairs. The conversation also delves into the importance of mentorship and continuous education for career building. The episode concludes with Carol's reflections on her journey and final thoughts for those navigating the industry.
My guest today is Carol Lawlor, National Director, Field Medical – Northeast at Alkermes, discusses her career resiliency story and how she overcame an unexpected lay off
Carol shares…
👉 Her medical background and industry transition
👉 How she landed in her first industry roll… and what happened next
👉 Advice for others suffering career setbacks
👉 What new areas or opportunities she sees developing
👉 Advice for those looking to build a career in medical affairs
medical affairs industry, career progression, industry layoffs, mentorship in medical affairs, career building strategies
Related Topics
You May Also Like
Tom Caravela
Podcast
MSL Talk: Tom Caravela, Sarah Snyder
The Ideal Roadmap for New MSLs
Podcast
MSL Talk: Tom Caravela, Cathy Andorfer
The ART of Excellence... How to be a Rock Star MSL
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS